1. Travis S., Dinesen L. Remission intrials of ulcerative colitis: what does it mean? Pract Gastroenterology. 2010; 30: 17 - 20.

2. D'Haens G., Sandborn W., Feagan B. et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132: 763 - 86.

3. Truelove S., Witts L. et al. Cortisone in ulcerative colitis; final report on a therapeutic trial Br Med J. 1955; 2: 1041 - 1048.

4. Dignass A., Eliakim R., Magro F. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis J Crohns Colitis. 2012 Dec; 6(10): 965 - 90. doi: 10.1016/j.crohns.2012.09.003

5. Cosnes J., Gower-Rousseau C., Seksik P. et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140: 1785 - 94.

6. Molodecky N., Soon I., Rabi D. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142(1): 46 - 54.

7. De Groof E., Rossen N., Van Rhijn B. et al. Burden of disease and increasing prevalence of inflammatory bowel disease in a populationbased cohort in the Netherlands. Eur. J. Gastroenterol Hepatol. 2016; 28: 1065 - 72.

8. Qiu Y., Wen Ren W., Liu Y. et al. Disease burden of inflammatory bowel disease in China from 1990 to 2017: Findings from the global burden of diseases 2017. E Clinical Medicine. 2020; 27:100544. doi: 10.1016/j.eclinm.2020.100544

9. Белоусова Е.А., Абдулганиева Д.И., Алексеева О.П. и соавт. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018; 46(5): 445 - 463. https://doi.org/10.18786/2072-0505-2018-46-5-445-463

10. Burisch J., Pedersen N., et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: The ECCO-EpiCom inception cohort. Gut. 2014; 63(4): 588 - 97.

11. Katsanos K.H., Vermeire S., Christodoulou D.K. et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion. 2007; 75: 113 - 21.

12. Silverberg M., Satsangi J., Ahmad T. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19: 5 - 36.

13. Seah D., De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016 Feb; 43(4): 482 - 513.

14. Hindryckx P., Jairath V., D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016 Nov; 13(11): 654 - 664.

15. Ачкасов С.И., Шапина М.В., Веселов В.В., Варданян А.В., Мингазов А.Ф., Пономаренко А.А. Предикторы колэктомии у пациентов со свертяжелым язвенным колитом. Колопроктология. 2020; 19(3): 37 - 48. https://doi.org/10.33878/2073-7556-2020-19-3-37-48

16. Chen J., Andrews J., Kariyawasam V. et al. IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther. 2016 Jul; 44(2): 127 - 44.

17. Schroeder K.H., Tremaine W., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 1625 - 9.

18. Григорьева Г.А., Мешалкина Н.Ю. О проблеме системных проявлений воспалительных заболеваний кишечника. Фарматека. 2011; N 15, с. 44 - 49.

19. Sands B. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004; 126: 1518 - 32.

20. Perler B., Ungaro R., Baird G., Malette M. et al. Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inceptive cohort. BMC Gastroenterol. 2019; 19: 47.

21. Fine K., Schiller L. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology. 1999; 116: 1464 - 86.

22. Forrest K., Symmons D., Foster P. Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? Aliment Pharmacol Ther. 2004; 20: 1035 - 43.

23. Mahid S.S., Minor K.S., Soto R.E. et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006; 81: 1462 - 71.

24. Vermeire S. Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment Pharmacol Ther. 2006; 24: 2 - 10.

25. Mogan G.R. et al. Toxic megacolon in ulcerative colitis complicated by pneumomediastinum: report of two cases//Gastroenterology. - 1980. - Т. 79. - N. 3. - С. 559 - 562.

26. Magro F., Gionchetti P., Eliakim R., Ardizzone S., Armuzzi A., Barreiro-de Acosta M., Burisch J., Gecse K.B., Hart A.L., Hindryckx P., Langner C., Limdi J.K., Pellino G., , Raine T., Harbord M., Rieder F.; European Crohn's and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017 Jun 1; 11(6): 649 - 670. doi: 10.1093/ecco-jcc/jjx008. Erratum in: J Crohns Colitis. 2022 Aug 16;: PMID: 28158501.

27. Travis S.P., Jewell D.P. Ulcerative colitis: clinical presentation and diagnosis. In: Satsangi J., Sutherland L.R., editors. Inflammatory Bowel Diseases. London: Churchill Livingstone. 2003: 169 - 81.

28. Lucendo A.J., , , , et al. Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients. Sao Paulo Med J. 2014; 132(3): 140 - 6.

29. Irwin J.R., Ferguson E., Simms L.A., Hanigan K. et al. Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn's Disease. Dig Dis Sci. 2019 Feb; 64(2): 503 - 517.

30. Cherfane C.E., Gessel L., Cirillo D., Zimmerman M.B., Polyak S. Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity. Inflamm Bowel Dis. 2015 Aug; 21(8): 1769 - 75.

31. Feng J.R., Qiu X., Wang F., Chen P.F., et al. Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn's Disease. Gastroenterol Res Pract. 2017. doi: 10.1155/2017/3526460

32. Yoon J.Y., Park S.J., Hong S.P., Kim T.I., et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014 Apr; 59(4): 829 - 37.

33. Yamamoto-Furusho J.K., , Uribe M. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann Hepatol. 2010 Oct-Dec; 9(4): 397 - 401.

34. Archampong E.Q., Harris J., Clark C.G. The absorption and secretion of water and electrolytes across the healthy and the diseased human colonic mucosa measured in vitro. Gut. 1972 Nov; 13(11): 880 - 6.

35. Maharshak N., Arbel Y., Gal-Oz A., Rogowski O., et al. Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease. J Dig Dis. 2008 Aug; 9(3): 140 - 3.

36. Weber P., Husemann S., Vielhaber H., Zimmer K.P., Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999 Apr; 28(4): 418 - 422.

37. Axelrad J.E1., Joelson A., Green P.H.R., Lawlor G. et al. Enteric Infections Are Common in Patients with Flares of Inflammatory Bowel Disease. Am J Gastroenterol. 2018 Oct; 113(10): 1530 - 1539. doi: 10.1038/s41395-018-0211-8

38. Issa M., Vikayapal A., Gracham M.B. et al. Impact of Clostridium difficile in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007; 5: 345 - 351.

39. Rodeman J.F., Dubberke E.R., Reske K.A. et al. Incidence of Clostridium difficile in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 339 - 344.

40. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1432 - 42.

41. Nguyen G.C., Kaplan G.G., Harris M.L. et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103: 1443 - 50.

42. Kim J.J., Simpson N., Klipfel N., Debose R., et al. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010 Apr; 55(4): 1059 - 65. doi: 10.1007/s10620-010-1126-4

43. Levin A., Yaari S., Stoff R., Caplan O., Wolf D.G., Israeli E. Diagnosis of Cytomegalovirus Infection during Exacerbation of Ulcerative Colitis.Digestion. 2017; 96(3): 142 - 148. doi: 10.1159/000479865.

44. Lin W.C., Chang C.W., Chen M.J., Hsu T.C., Wang H.Y. Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response. Medicine (Baltimore). 2019 May; 98(21): e15748. doi: 10.1097/MD.0000000000015748

45. Bansal J., Jenaw R.K., Rao J. et al. Effectiveness of plain radiography in diagnosing hollow viscus perforation: study of 1,723 patients of perforation peritonitis. Emerg Radiol. 2012 Apr; 19(2): 115 - 9. doi: 10.1007/s10140-011-1007-y.

46. Annese V., Daperno M., Rutter M.D. et al. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis. 2013; 7(12): 982 - 1018.

47. Tanaka M., Saito H., Fukuda S., Sasaki Y. et al. Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis, and other forms of colitis: measurement of validity. Scand J Gastroenterol. 2000 Mar; 35(3): 281 - 6.

48. Parente F., Greco S., Molteni M. et al. Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel. Alimentary Pharmacology and Therapeutics. 2003; 18: 1009 - 1016.

49. Baltarowich O.H., Scoutt L. M., Hamper U. M. Nongynecologic findings on pelvic ultrasound: focus on gastrointestinal diseases//Ultrasound Quarterly. - 2012. - Т. 28. - N. 2. - С. 65 - 85.

50. Smith R., Taylor K., Friedman A.B. et al. Systematic Review: Clinical Utility of Gastrointestinal Ultrasound in the Diagnosis, Assessment and Management of Patients With Ulcerative Colitis. J Crohns Colitis. 2020 May 21; 14(4): 465 - 479. doi: 10.1093/ecco-jcc/jjz163

51. , Soylu A., , , et al. Is quantitative diffusion-weighted MRI a reliable method in the assessment of the inflammatory activity in ulcerative colitis? Diagn Interv Radiol. 2010 Dec; 16(4): 293 - 8. doi: 10.4261/1305-3825.DIR.2989-09.1

52. Jia Y., Li C., Yang X., Dong Z. et al. CT Enterography score: a potential predictor for severity assessment of active ulcerative colitis. BMC Gastroenterol. 2018 Nov 9; 18(1): 173. doi: 10.1186/s12876-018-0890-z

53. Gashin L., Villafuerte-Galvez J., Leffler D.A. et al. Utility of CT in the emergency department in patients with ulcerative colitis. Inflamm Bowel Dis. 2015 Apr; 21(4): 793 - 800. doi: 10.1097/MIB.0000000000000321

54. Милько В.И., Минцер О.П., Топчий Т.В., Корсуновский А.А. Клиническая оценка данных ирригоскопии при неспецифическом язвенном колите. Вест. Рентгенологии и радиологии. 1983; N 5, с. 46 - 50.

55. Fraser G.M., Findlay J.M. The double contrast enema in ulcerative and Crohn's colitis. Clin Radiol. 1976 Jan; 27(1): 103 - 12.

56. Ивашкин В.Т., Шептулин А.А., Шифрин О.С., Галимова С.Ф., и соавт. Микроскопический колит: клинические формы, диагностика, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006; т. 16, N 6, с. 56 - 60.

57. Peyrin-Biroulet L., Sandborn W., Sands B. et al. Selecting Therapeutic Targets inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015; 110(9): 1324 - 1338. https://doi.org/10.1038/ajg.2015.233

58. Turner D., Ricciuto A., Lewis A. et al.; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Apr; 160(5): 1570 - 1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19. PMID: 33359090

59. Халиф И.Л. Лечебная тактика при язвенном колите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006; т. 16, N 3, с. 58 - 62.

60. Белоусова Е.А., Никитина Н.В., Цодикова О.М. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека. 2013; N 2, с. 42 - 46.

61. Reinisch W. Reinink A., Higgins P. Factors Associated With Poor Outcomes in Adults With Newly Diagnosed Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2015; 13: 635 - 642.

62. Dias C.C., Rodrigues P.P., da Costa-Pereira A. et al. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015; 9: 156 - 63.

63. Annese V., Beaugerie L., Egan L., Biancone L., Bolling C., Brandts C. et al. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015; 9(11): 945 - 65.

64. Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А. и соавт. Раннее назначение генно-инженерных биологических препаратов при иммуновоспалительных заболеваниях: возможности и перспективы. Позиция экспертов.//Альманах клинической медицины. - 2020. - Т. 48. - N 6. - С. 422 - 436. doi: 10.18786/2072-0505-2020-48-050

65. Dinesen L.C., Walsh A.J., Protic M.N., Heap G. et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010; 4(4): 431 - 437. https://doi.org/10.1016/j.crohns.2010.02.001

66. Marshall J.K., Thabane M., Steinhart A.H., Newman J.R. et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. 2010, Issue 1. Art. No.: CD004115. doi: 10.1002/14651858.CD004115

67. Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 2011; 56: 513 - 2256,57.

68. Marshall J.K., Irvine E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997; 40: 775 - 81.

69. Pokrotnieks J., Sitkin S. A proposed treatment algorithm for mild to moderate ulcerative colitis-with an emphasis on budesonide foam and mucosal healing. J Gastroenterol. 2018 Jun; 53(6): 799 - 800. doi: 10.1007/s00535-018-1458-y

70. Regueiro M., Loftus Jr E.V., Steinhart A.H., Cohen R.D. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006; 12: 979 - 94.

71. Safdi M., DeMicco M., Sninsky C., Banks P. et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997; 92: 1867 - 71.

72. Timmer A., Patton P.H., Chande N., McDonald J.W., MacDonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016 May 18; (5): CD000478. doi: 10.1002/14651858.CD000478.pub4

73. Ahmed I., Kassem W., Salam Y., Furnari M, Mehta T. Outcome of Cytomegalovirus Colitis in Inflammatory Bowel Disease with Different Regimes of Ganciclovir. Middle East J DigDis. 2018 Oct; 10(4): 220 - 229. doi: 10.15171/mejdd.2018.114

74. Sutherland L., Macdonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006: CD000543.

75. Ford A.C., Achkar J-P., Khan K.J., Kane S.V., Talley N.J. et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106: 601 - 16.

76. Ford A.C., Khan K.J., Achkar J.P. et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. The American journal of gastroenterology. 2012; 107: 167 - 76.

77. Nikfar S. et al. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of imp rovement and maintenance of remission in patients with ulcerative colitis. Digestive diseases and sciences. 2009; 54(6): 1157 - 1170.

78. Kane S.V., Bjorkman D.J. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord. 2003; 3: 210 - 8.

79. Zhang Y., Chen D., Wang F., Li X., Xue X. et al. Comparison of the efficiency of different enemas on patients with distal ulcerative colitis. Cell Prolif. 2019 Mar; 52(2): e12559. doi: 10.1111/cpr.12559. Epub 2019 Jan 18

80. Danielsson A., , Persson T., Salde L. et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol. 1992; 27(1): 9 - 12.

81. Nguyen N.H., Fumery M., Dulai P.S., Prokop L.J. et al. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018 Nov; 3(11): 742 - 753. doi: 10.1016/S2468-1253(18)30231-0

82. D'Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther. 2016; 44: 1018 - 1029.

83. Hartmann F1, Stein J.; BudMesa-Study Group. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2010 Aug; 32(3): 368 - 76.

84. Gross V1., Bar-Meir S., Lavy A., Mickisch O. et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther. 2006 Jan 15; 23(2): 303 - 12.

85. Matzen P. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. The Danish Budesonide Study Group. Scand J Gastroenterol. 1991 Dec; 26(12): 1225 - 30.

86. Lichtenstein G.R. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Dig Dis Sci. 2016 Feb; 61(2): 358 - 70.

87. Sherlock M.E., MacDonald J.K., Griffiths A.M., Steinhart A.H., Seow C.H. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015 Oct 26; (10): CD007698.

88. Danese S., Siegel C.A., Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014 May; 39(10): 1095 - 103.

89. Gisbert J.P., Linares P.M., McNicholl A.G., Mate J., Gomollon F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009; 30: 126 - 37.

90. Rutgeerts P., Sandborn W.J., Feagan B.G. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine. 2005; 353: 2462 - 2476.

91. Sandborn W.J., van Assche G., Reinisch W. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012; 142: 257 - 65 e1-3.

92. Sandborn W.J., Feagan B.G., Marano C. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014; 146: 85 - 95; quiz e14-5.

93. Feagan B.G., Rutgeerts P., Sands B.E. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England journal of medicine. 2013; 369: 699 - 710.

94. Sandborn W.S.B., D'Haens G.R. et al. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials. Gastroenterology. 2016: S157

95. Danese S., Vermeire S. et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022 Jun 4; 399(10341): 2113 - 2128. doi: 10.1016/S0140-6736(22) 00581-5

96. Sandborn W., Feagan B.G. et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis N Engl J Med. 2021 Sep 30; 385(14): 1280 - 1291. doi: 10.1056/NEJMoa2033617

97. Panaccione R., Ghosh S., Middleton S. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014; 146: 392 - 400.e3.

98. Panaccione R., Ghosh S., Middleton S. et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J Crohns Colitis. 2011; 5: 1376 - 1380. doi: 10.1002/14651858.CD000478

99. Yarur A.J., Rubin D.T. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015 Jul; 21(7): 1709 - 18.

100. Steenholdt C., Bendtzen K., Brynskov J., Ainsworth M.A. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflamm Bowel Dis. 2016 Aug; 22(8): 1999 - 2015.

101. Sandborn W.J., Su C., Sands B.E. et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017; 376: 1723 - 36.

102. Reinisch W., Sandborn W.J., Rutgeerts P. et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012; 18: 201 - 11.

103. Danese S., D'Amico F., Bonovas S., Peyrin-Biroulet L. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis. 2018; 24(10): 2106 - 2112. doi: 10.1093/ibd/izy076

104. Sands B.E., Sandborn W.J., Panaccione R. et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019 Sep 26; 381(13): 1201 - 1214. doi: 10.1056/NEJMoa1900750

105. Singh S., Fumery M., Sandborn W.J., Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 Jan; 47(2): 162 - 175. doi: 10.1111/apt.14422

106. Shmidt E., Kochhar G., Hartke J. et al. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory. Inflamm Bowel Dis. 2018; 24(11): 2461 - 2467. doi: 10.1093/ibd/izy171

107. Sands B.E., Armuzzi A., Marshall J.K. et al. DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open. J Crohns Colitis. 2018; 12: 49, https://doi.org/10.1093/ecco-jcc/jjx180.063.

108. Turner D., Walsh C.M., Steinhart A.H. et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007; 5: 103 - 110.

109. Dignass A.U., Gasche C., Bettenworth D. et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015; 9: 211 - 22.

110. Gonzalez-Huix F., Fernandez-Banares F., Esteve-Comas M. et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol. 1993; 88: 227 - 32.

111. Parlak E., , Ulker A. et al. Comparison of 5-aminosalicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis. J Clin Gastroenterol. 200; 33(1): 85 - 6.

112. Khan K.J., Ullman T.A., Ford A.C., Abreu M.T. et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011; 106: 661 - 73.

113. Ohkusa T., Kato K., Terao S., Chiba T. et al. Newly developed antibiotic combination therapy for ulcerativecolitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010; 105: 1820 - 9.

114. Sokol H., Seksik P., Carrat F., Nion-Larmurier I. et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010; 59: 1363 - 8.

115. Chebli L.A., Chaves L.DdM., Pimentel F.F., Guerra D.M. et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 613 - 9.

116. Ardizzone S., Maconi G., Russo A., Imbesi V. et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006; 55: 47 - 53.

117. Халиф И.Л., Нанаева Б.А., Головенко А.О., Головенко О.В. Отдаленные результаты консервативного лечения больных с тяжелым обострением язвенного колита. Терапевтический архив. 2015; 87(2): 34 - 38. https://doi.org/10.17116/terarkh201587234-38.

118. , Hertervig E., Friis-Liby I. et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128: 1805 - 11.

119. Lees C.W., Heys D., Ho G.T., Noble C.L. et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007; 26: 411 - 9

120. Van Assche G., D'Haens G., Noman M., Vermeire S. et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003; 125: 1025 - 31.

121. Sjoberg M., Walch A., Meshkat M., Gustavsson A. et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis. 2012; 18(2): 212 - 8.

122. Головенко А.О., Халиф И.Л., Головенко О.В., Веселов В.В. Предикторы эффективности инфликсимаба у больных с тяжелой атакой язвенного колита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013.5(23): 65 - 73.

123. Lennard-Jones J.E., Ritchie J.K., Hilder W., Spicer C.C. Assessment of severity in colitis: a preliminary study. Gut. 1975; 16: 579 - 84.

124. Travis S.P., Farrant J.M., Ricketts C., Nolan D.J. et al. Predicting outcome in severe ulcerative colitis. Gut. 1996; 38: 905 - 10.

125. Cima R.R. Timing and indications for colectomy in chronic ulcerative colitis: surgical consideration//Digestive diseases. - 2010. - Т. 28. - N. 3. - С. 501 - 507

126. Provenzale D. et al. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis//Gastroenterology. - 1995. - Т. 109. - N. 4. - С. 1188 - 1196.

127. Jess T., Loftus Jr E.V., Velayos F.S., Harmsen W.S. et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006; 130: 1039 - 46.

128. Odze R.D. et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis//Clinical Gastroenterology and Hepatology. - 2004. - Т. 2. - N. 7. - С. 534 - 541.

129. Fumery M. et al. Colonic strictures in inflammatory bowel disease: epidemiology, complications, and management//Journal of Crohn's and Colitis. - 2021. - Т. 15. - N. 10. - С. 1766 - 1773.

130. Feuerstein J.D., Rakowsky S., Sattler L. et al. Meta-analysis of dye-based chromoendoscopy compared with standard- and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. Gastrointest Endosc. 2019; 90: 186 - 195.

131. Iannone A., Ruospo M., Wong G. et al. Chromoendoscopy for surveillance in ulcerative colitis and crohn's disease: a systematic review of randomized trials. Clin Gastroenterol Hepatol 2017; 15: 1684 - 1697.

132. Bessissow T., Dulai P.S., Restellini S. et al. Comparison of endoscopic dysplasia detection techniques in patients with ulcerative colitis: a systematic review and network meta-analysis. Inflamm Bowel Dis 2018; 24: 2518 - 2526.

133. Alkandari A., Thayalasekaran S., Bhandari M. et al. Endoscopic Resections in Inflammatory Bowel Disease: A Multicentre European Outcomes Study. J Crohns Colitis. 2019; 28: 13(11): 1394 - 1400.

134. Kinoshita S., Uraoka T., Nishizawa T. et al. The role of colorectal endoscopic submucosal dissection in patients with ulcerative colitis. Gastrointest Endosc. 2018; 87(4): 1079 - 1084.

135. Andersen K., Vogt C., Blondin D. et al. Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. Eur J Radiol. 2006; 58: 140 - 6.

136. Richards D.M., Hughes S.A., Irving M.H., Scott N.A. Patient quality of life after successful restorative proctocolectomy is normal. Colorectal Dis. 2001; 3: 223 - 6.

137. McLaughlin S.D., Clark S.K., Thomas-Gibson S., Tekkis P. et al. Guide to endoscopy of the ileo-anal pouch following restorative proctocolectomy with ileal pouch-anal anastomosis; indications, technique, and management of common findings. Inflamm Bowel Dis. 2009; 15: 1256 - 63.

138. Marcello P.W., Roberts P.L., Schoetz Jr D.J., Coller J.A. et al. Long-term results of the ileoanal pouch procedure. Arch Surg. 1993; 128: 500 - 3 [discussion 503 - 4].

139. Sagar P.M., Pemberton J.H. Ileo-anal pouch function and dysfunction. Dig Dis. 1997; 15: 172 - 88.

140. Meagher A.P., Farouk R., Dozois R.R., Kelly K.A. et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998; 85: 800 - 3.

141. Fleming F.J., Francone T.D., Kim M.J., Gunzler D., Messing S., Monson J.R. A laparoscopic approach does reduce short-term complications in patients undergoing ileal pouch-anal anastomosis. Dis Colon Rectum. 2011; 54: 176 - 82.

142. Colombo F., Pellino G., Selvaggi F. et al. Minimally invasive surgery and stoma-related complications after restorative proctocolectomy for ulcerative colitis. A two-centre comparison with open approach. Am J Surg. 2019; 217: 682 - 8.

143. Ahmed A., Keus F., Heikens J. et al. Open versus laparoscopic [assisted] ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. Cochrane Database Syst Rev. 2009; 1: CD006267.

144. Tilney H.S., Lovegrove R.E., Heriot A.G. et al. Comparison of short-term outcomes of laparoscopic vs open approaches to ileal pouch surgery. Int J Colorectal Dis. 2007; 22: 531 - 42.

145. Hull T.L., Joyce M.R., Geisler D.P., Coffey J.C. Adhesions after laparoscopic and open ileal pouch-anal anastomosis surgery for ulcerative colitis. Br J Surg. 2012; 99: 270 - 5.

146. Sofo L., Caprino P., Sacchetti F., Bossola M. Restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a narrative review. World J Gastrointest Surg. 2016; 8: 556 - 63.

147. Setti-Carraro P., Ritchie J.K., Wilkinson K.H. et al. The first 10 years' experience of restorative proctocolectomy for ulcerative colitis. Gut. 1994; 35: 1070 - 1075.

148. Fazio V.W., Ziv Y., Church J.M. et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995; 222: 120 - 127.

149. Belliveau P., Trudel J., Vasilevsky C.A. et al. Ileoanal anastomosis with reservoirs: complications and long-term results. Can J Surg. 1999; 42: 345 - 352.

150. Pinto R.A., Canedo J., Murad-Regadas S., Regadas S.F. et al. Ileal pouch-anal anastomosis in elderly patients: is there a difference in morbidity compared with younger patients? Colorectal Dis. 2011; 13: 177 - 83.

151. Church J.M. Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. Aust N Z J Surg. 2000; 70: 906 - 7.

152. Chapman J.R., Larson D.W., Wolff B.G., Dozois E.J. et al. Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome? Arch Surg. 2005; 140: 534 - 40.

153. Delaney C.P., Dadvand B., Remzi F.H. et al. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. Dis Colon Rectum. 2002; 45: 890 - 4.

154. Olsen K.O., Joelsson M., Laurberg S., Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg. 1999; 86: 493 - 5.

155. Ording O.K., Juul S., Berndtsson I., Oresland T. et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology. 2002; 122: 15 - 9.

156. Gorgun E., Remzi F.H., Goldberg J.M., Thornton J. et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery. 2004; 136: 795 - 803.

157. Johnson P., Richard C., Ravid A., Spencer L. et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2004; 47: 1119 - 26.

158. Oresland T., Palmblad S., Ellstrom M., Berndtsson I. et al. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int J Colorectal Dis. 1994; 9: 77 - 81.

159. Alves A., Panis Y., Bouhnik Y., Maylin V. et al. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg. 2003; 197: 379 - 85

160. Berg D.F., Bahadursingh A.M., Kaminski D.L., Longo W.E. Acute surgical emergencies in inflammatory bowel disease. Am J Surg. 2002; 184: 45 - 51.

161. Hyman N.H., Cataldo P., Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum. 2005; 48: 70 - 3.

162. Holubar S.D., Larson D.W., Dozois E.J., Pattana-Arun J. et al. Minimally invasive subtotal colectomy and ileal pouch-anal anastomosis for fulminant ulcerative colitis: a reasonable approach? Dis Colon Rectum. 2009; 52: 187 - 92.

163. Marceau C., Alves A., Ouaissi M., Bouhnik Y. et al. Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. Surgery. 2007; 141: 640.

164. Annibali R., Oresland T., Hulten L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? Dis Colon Rectum. 1994; 37: 321 - 9.

165. Burns E.M., Bottle A., Aylin P., Clark S.K. et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg. 2011; 98: 408 - 17.

166. Tekkis P.P., Fazio V.W., Lavery I.C., Remzi F.H. et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. Ann Surg. 2005; 241: 262 - 8.

167. Lepisto A. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. Scand J Surg. 2005; 94: 40 - 2.

168. Edwards, C.M., George B., Warren F. Diversion colitis: new light through old windows. Histopathology. 1999.35(1): 86 - 7.

169. Shepherd N.A., Jass J.R., Duval I., Moskowitz R.L. et al. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol. 1987; 40: 601 - 7.

170. SettiCarraro P.G., Talbot I.C., Nicholls J.R. Patterns of distribution of endoscopic and histological changes in the ileal reservoir after restorative proctocolectomy for ulcerative colitis. A long-term follow-up study. Int J Colorectal Dis. 1998; 13: 103 - 7.

171. Ferrante M., D'Hoore A., Vermeire S. et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 1062 - 70.

172. Lake J.P., Firoozmand E., Kang J.C., Vassiliu P. et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J Gastrointest Surg. 2004; 8: 547 - 51.

173. Mahadevan U., Loftus Jr E.V., Tremaine W.J., Pemberton J.H., Harmsen W.S., Schleck C.D. et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis. 2002; 8: 311 - 6.

174. Pugliese D., Armuzzi A., Rizzo G. et al. Effect of anti-TNF-alpha treatment on short-term post-operative complications in patients with inflammatory bowel disease. Gut. 2010; 59 (Suppl III): A13.

175. Subramanian V., Pollok R.C., Kang J.Y., Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg. 2006; 93: 793 - 9.

176. Yang Z., Wu Q., Wang F., Wu K., Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther. 2012 Nov; 36(10): 922 - 8. doi: 10.1111/apt.12060. Epub 2012 Sep 24

177. Meagher A.P., Farouk R., Dozois R.R., Kelly K.A. et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998; 85: 800 - 3.

178. Simchuk E.J., Thirlby R.C. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg. 2000; 24: 851 - 6.

179. Stahlberg D., Gullberg K., Liljeqvist L., Hellers G. et al. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum. 1996; 39: 1012 - 8.

180. Penna C., Tiret E., Kartheuser A., Hannoun L. et al. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br J Surg. 1993; 80: 765 - 7.

181. Tjandra J.J., Fazio V.W., Church J.M., Oakley J.R. et al. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg. 1993; 165: 322 - 5.

182. Poo S., Sriranganathan D., Segal J.P. Network meta-analysis: efficacy of treatment for acute, chronic, and prevention of pouchitis in ulcerative colitis//European Journal of Gastroenterology & Hepatology. - 2022. - Т. 34. - N. 5. - С. 518 - 528

183. Viazis N., Giakoumis M., Koukouratos T. et al. Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis, Journal of Crohn's and Colitis. 2013; 7(10): 457 - 460.

184. Travis S., Silverberg M.S., Danese S. et al. OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial. Journal Crohns Colitis. 2022; 16 (Supplement_1): i004-5

185. Peter J., Zeitz J., Stallmach A. Ustekinumab Rescue Therapy in a Patient With Chronic Refractory Pouchitis. Journal of Crohn's and Colitis. 2018; 12(8): 1008 - 1009.

186. Сухина М.А., Образцов И.В., Михалевская В.И., Ачкасов С.И., Сафин А.Л., Шелыгин Ю.А. Алгоритм лабораторной диагностики clostridium difficile-ассоциированной диареи. Журнал микробиологии, эпидемиологии и иммунобиологии (ЖМЭИ). 2018; (2): 45 - 53.

187. Шелыгин Ю.А., Алешкин В.А., Сухина М.А., Миронов А.Ю., и др. Клинические рекомендации национальной ассоциации специалистов по контролю инфекций, связанных с оказанием медицинской помощи, и общероссийской общественной некоммерческой организации "Ассоциация колопроктологов России" по диагностике, лечению и профилактике Clostridium difficile-ассоциированной диареи (cdi). Колопроктология. 2018; (3): 7 - 23. https://doi.org/10.33878/2073-7556-2018-0-3-7-23.

188. Aguado J.M., Anttila V.J., Galperine T., Goldenberg S.D. et al. Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line. J Hosp Infect. 2015; 2(50): 117 - 125.

189. Metan G., , Kaynar L. Tigecycline for the treatment of Clostridium difficile infection refractory to metronidazole in haematopoietic stem cell transplant recipients. Journal of Chemotherapy. 2015; 6(27): 354 - 357.

190. Chiu C.Y., Sarwal A., Feinstein A., Hennessey K. Effective Dosage of Oral Vancomycin in Treatment for Initial Episode of Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2019 Oct 1; 8(4). pii: E173. doi: 10.3390/antibiotics8040173.

191. Tschudin-Sutter S., Braissant O., Erb S. et al. Growth Patterns of Clostridium difficile - Correlations with Strains, Binary Toxin and Disease Severity: A Prospective Cohort Study. PLoS One. 2016; 9(11): e0161711.

192. Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., Алешин Д.В., и соавт. Современные возможности улучшения функционального состояния запирательного аппарата у пациентов с наличием превентивных кишечных стом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015; N 5, с. 77 - 83.

193. Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., Джанаев Ю.А., и соавт. Роль аноректальной манометрии, БОС-терапии и тибиальной нейромодуляции в диагностике и консервативном лечении анальной инконтиненции у пожилых. Клиническая геронтология. 2015; N 5 - 6, с. 16 - 20.

194. Rahier J.F., Magro F., Abreu C., Armuzzi A. et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. JCrohns Colitis. 2014 Jun; 8(6): 443 - 68. doi: 10.1016/j.crohns.2013.12.013. Epub 2014 Mar 6

195. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005.172(9): 1169 - 227.

196. Franchimont D., Ferrante M., Louis E. et al. Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD); Acta Gastroenterol Belq 2018; 81: 49 - 53.

197. Lin W.C., Chang C.W., Chen M.J., Hsu T.C., Wang H.Y. Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response. Medicine (Baltimore). 2019 May; 98(21): e15748. doi: 10.1097/MD.0000000000015748

198. Colombel J.F., , Ullman T., Rutgeerts P. et al. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. Gastroenterology. 2016 Feb; 150(2): 389 - 95. e3. doi: 10.1053/j.gastro.2015.10.016

199. Annese V., Daperno M., Rutter M.D. et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013; 7(12): 982 - 1018.

200. Puolanne A.M., Kolho K.L., Alfthan H., Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study. Scand J Gastroenterol. 2019 Jul; 54(7): 849 - 854. doi: 10.1080/00365521.2019.1618910

201. Kato J., Yoshida T., Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol. 2019 Jun; 15(6): 667 - 677. doi: 10.1080/1744666X.2019.1593140

202. Князев О.В., Каграманова А.В., Корнеева И.А. и соавт. Значение фекального кальпротектина в мониторинге активности воспалительных заболеваний кишечника. Терапевтический архив. 2019; 91 (4): 53 - 61. DOI: 10.26442/00403660.2019.04.000229

203. Trigo-Vicente C., Gimeno-Ballester V. et al. Systematic review and network meta-analysis of treatmentfor moderate-to-severe ulcerative colitis. Int J Clin Pharm. 2018 Dec; 40(6): 1411 - 1419. doi: 10.1007/s11096-018-0743-4

204. Nguyen G.C., Bernstein C.N., Bitton A. et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014; 146: 835 - 848.

205. Olivera P., Zuily S. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 Dec; 18(12): 857 - 873. doi: 10.1038/s41575-021-00492-8

206. Подольская Д.В., Шапина М.В., Баранова Т.А., Тишаева И.А., Александров Т.Л., Князев О.В., Нанаева Б.А. Эффективность тофацитиниба в качестве "терапии спасения" у пациентов с язвенным колитом тяжелой степени. Колопроктология. 2021; 20(3): 43 - 50. https://doi.org/10.33878/2073-7556-2021-20-3-43-50

207. Kotwani P., Terdiman J., Lewin S. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience. J CrohnsColitis. 2020 Jul 30; 14(7): 1026 - 1028. doi: 10.1093/ecco-jcc/jjaa018

208. Xiao Y., Benoit N., Sedano R. Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case Series. Dig Dis Sci. 2022. doi: 10.1007/s10620-022-07439-2

209. Goetgebuer L. et al. Kreijne Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study. Journal of Crohn's and Colitis. 2021, 1464 - 1473. doi: 10.1093/ecco-jcc/jjab036

210. Sands B., Peyrin-Biroulet L., Loftus E. et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019 Sep 26; 381(13): 1215 - 1226. doi: 10.1056/NEJMoa1905725

211. Bressler B., Yarur A., Silverberg M. et al. Vedolizumab and Anti-Tumour Necrosis Factor Real-World Outcomes in Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 7; 15(10): 1694 - 1706. doi: 10.1093/ecco-jcc/jjab058

212. Bressler B., Yarur A., Kopylov U. et al. Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients with Ulcerative Colitis or Crohn's Disease. United European Gastroenterol J. 2019; 7(8 (Supplement)). Poster P1091.

213. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) EMA/CHMP/BWP/247713/2012. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Last accessed: September 2022.

214. IQVIA. The impact of biosimilar competition in Europe. 2021. Available at: https://www.iqvia. com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021.pdf. Last accessed: 17 October 2022.

215. Humphry N. The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance. EMJ Gastroenterol. 2022; 11 [Suppl 7]: 2 - 10. https://doi.org/10.33590/emjgastroenterol/10106137.

216. Danese S., Fiorino G., Raine T. et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis. 2017; 11: 26 - 34.

217. Cohen H., Blauvelt A., Rifkin R.M. et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018; 78: 463 - 78.

218. Massimi D., Barberio B., Bertani L. et al. Switching from infliximab originator to SB2 biosimilar in inflammatory bowel diseases: a multicentric prospective real-life study. Ther Adv Gastroenterol. 2021; 14: 1 - 11.

219. Trystram N., Abitbol V., Tannoury J. et al. Outcomes after double switching from originator infliximab to biosimilar CT-P13 and biosimilar SB2 inpatients with inflammatory bowel disease: a 12-month prospective cohort study. Aliment Pharmacol Ther. 2021; 53: 887 - 99.

220. Mahmmod S., Schultheiss J.P.D, van Bodegraven A.A. et al. Outcome of reverse switching from CT-P13 to originator infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021; 27: 1954 - 62.

221. Kaniewska M., Rosolowski M., Moniuzsko A. et al. Biosimilar infliximab versus originator in Crohn's disease and patients. Prz Gastroenterol. 2021; 16: 207 - 12.

222. Morris G.A., McNikol M., Boyle B. et al. Increasing biosimilar utilization at a pediatric inflammatory bowel disease center and associated cost savings: show me the money. Inflamm Bowel Dis. 2022; 28: 531 - 8.

223. Barberio B. Cingolani L., Canova C. et al. A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. Ther Adv Gastroenterol. 2021; 14: 175 - 82.

224. Kurki P., Barry S., Bourges I. et al. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021; 81: 1881 - 96.

225. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017 Jan; 11(1): 3 - 25. doi: 10.1093/ecco-jcc/jjw168. Epub 2016 Sep 22.

226. , Arranz E.M., , Arranz M. What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF? A. Cerpa Arencibia, C. Suarez Ferrer. Journal of Crohn s and Colitis. January 2020; 14 (Supplement_1): S554 - S554.

227. Stavem K. Switching from one reference biological to another in stable patients for non-medical reasons: a literature search and brief review. J Mark Access Health Policy. 2021; 9(1): 1964792. Published online 2021 Aug 20. DOI: 10.1080/20016689.2021.1964792 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381978/

228. Князев О.В., Звяглова М.Ю., Каграманова А.В. и соавт. Потеря ответа и частота нежелательных явлений у пациентов с язвенным колитом и болезнью Крона при переходе с оригинального препарата инфликсимаб на его биосимиляры. Терапевтический архив. 2021; 93 (2): 150 - 157. DOI: 10.26442/00403660.2021.02.200624.

229. Gisbert J.P. et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis//Alimentary pharmacology & therapeutics. - 2009. - Т. 30. - N. 2. - С. 126 - 137.

230. Sood A. et al. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial//Indian journal of gastroenterology: official journal of the Indian Society of Gastroenterology. - 2000. - Т. 19. - N. 1. - С. 14 - 16.

231. Kuriyama M. et al. Tolerability and usefulness of mercaptopurine in azathioprine-intolerant Japanese patients with ulcerative colitis//Digestive Endoscopy. - 2010. - Т. 22. - N. 4. - С. 289 - 296

232. Meier J., Sturm A. Current treatment of ulcerative colitis//World journal of gastroenterology: WJG. - 2011. - Т. 17. - N. 27. - С. 3204.

233. Ng S.C., Kamm M.A. Therapeutic strategies for the management of ulcerative colitis//Inflammatory bowel diseases. - 2009. - Т. 15. - N. 6. - С. 935 - 950

234. Абдулхаков С.Р., Абдулхаков Р.А. Неспецифический язвенный колит: современные подходы к диагностике и лечению//Вестник современной клинической медицины. - 2009. - Т. 2. - N. 1. - С. 32 - 41.

235. O. Petitjean, J.L. Wendling, M. Tod, et all/Pharrnacokinetics and absolute rectal bioavaila bility of hydrocortisone acetate in distal colitis//Aliment. Pharmacol. Ther. (1992) 6, 351 - 357.

236. Lloyd R. Sutherland. Topical Treatment of Ulcerative Colitis//Medical Clinics of North America-Vol.74, No. 1, January 1990

237. Pleet J.L. et al. The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis//Alimentary pharmacology & therapeutics. - 2014. - Т. 39. - N. 9. - С. 940 - 948

238. Sands B.E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis//New England Journal of Medicine. - 2019. - Т. 381. - N. 13. - С. 1201 - 1214.

239. Sandborn W.J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis//New England Journal of Medicine. - 2017. - Т. 376. - N. 18. - С. 1723 - 1736.

240. Gies N. et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort//Alimentary pharmacology & therapeutics. - 2010. - Т. 32. - N. 4. - С. 522 - 528.

241. Gemayel N.C. et al. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence//Current Medical Research and Opinion. - 2019. - Т. 35. - N. 11. - С. 1911 - 1923.

242. Burr N.E. et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis//Gut. - 2022. - Т. 71. - N. 10. - С. 1976 - 1987.

243. Travis S.P.L. et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study//Gut. - 2014. - Т. 63. - N. 3. - С. 433 - 441.

244. Panaccione R. et al. Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review//Advances in Therapy. - 2023. - Т. 40. - N. 5. - С. 2051 - 2081.

245. Sofia M.A., Rubin D.T. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis//Therapeutic advances in gastroenterology. - 2016. - Т. 9. - N. 4. - С. 548 - 559.

246. Ferretti F. et al. An update on current pharmacotherapeutic options for the treatment of ulcerative colitis//Journal of Clinical Medicine. - 2022. - Т. 11. - N. 9. - С. 2302.

247. Pleet J.L. et al. The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis//Alimentary pharmacology & therapeutics. - 2014. - Т. 39. - N. 9. - С. 940 - 948

248. Christophorou D. et al. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis//Alimentary Pharmacology & Therapeutics. - 2015. - Т. 41. - N. 7. - С. 603 - 612

249. Woolrich A.J., DaSilva M.D., Korelitz B.I. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia//Gastroenterology. - 1992. - Т. 103. - N. 2. - С. 431 - 438.

250. Gionchetti P. et al. Oral budesonide in the treatment of chronic refractory pouchitis//Alimentary pharmacology & therapeutics. - 2007. - Т. 25. - N. 10. - С. 1231 - 1236.

251. Segal J.P. et al. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm//Alimentary Pharmacology & Therapeutics. - 2017. - Т. 45. - N. 5. - С. 581 - 592.

252. Khoo E. et al. Systematic Review and Meta-analysis of Immunomodulator and Biologic Therapies for Treatment of Chronic Pouchitis//medRxiv. - 2021. - С. 2021.01. 19.21250059

253. Rao K., Higgins P.D.R. Epidemiology, diagnosis, and management of Clostridium difficile infection in patients with inflammatory bowel disease//Inflammatory bowel diseases. - 2016. - Т. 22. - N. 7. - С. 1744 - 1754.

254. Silva J. et al. Treatment of Clostridium difficile colitis and diarrhea with vancomycin//The American Journal of Medicine. - 1981. - Т. 71. - N. 5. - С. 815 - 822.

255. Nitzan O. et al. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment//World journal of gastroenterology: WJG. - 2013. - Т. 19. - N. 43. - С. 7577.

256. Bamba S. et al. Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis//Journal of gastroenterology and hepatology. - 2010. - Т. 25. - N. 3. - С. 494 - 498.

257. Papa A., Gerardi V., Marzo M., Felice C., Rapaccini G.L., Gasbarrini A. Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. World J Gastroenterol. 2014 Mar 28; 20(12): 3173 - 9. doi: 10.3748/wjg.v20.i12.3173.

258. Tinsley A., Naymagon S., Enomoto L.M., Hollenbeak C.S., Sands B.E., Ullman T.A. Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. J Crohns Colitis. 2013 Dec; 7(12): e635 - 40. doi: 10.1016/j.crohns.2013.05.002

259. Lightner A.L., Sklow B., Click B., Regueiro M., McMichael J.J., Jia X., Vaidya P., Delaney C.P., Cohen B., Wexner S.D., Steele S.R., Holubar S.D. Venous Thromboembolism in Patients Admitted for IBD: An Enterprise-Wide Experience of 86,000 Hospital Encounters. Dis Colon Rectum. 2023 Mar 1; 66(3): 410 - 418. doi: 10.1097/DCR.0000000000002338

260. Hiroshi N., (2022). Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy. Gut and Liver. 17. 10.5009/gnl220017.

261. Singh S., Allegretti J.R., Siddique S.M., Terdiman J.P. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020 Apr; 158(5): 1465 - 1496. e17. doi: 10.1053/j.gastro.2020.01.007. Epub 2020 Jan 13. PMID: 31945351; PMCID: PMC7117094.

262. Wenjie Xi, Zongwei Li, Rongrong Ren, Xiao-Yong Sai, Lihua Peng&Yunsheng Yang (2020): Effect of antibiotic therapy in patients with ulcerative colitis: a metaanalysis of randomized controlled trials, Scandinavian Journal of Gastroenterology, DOI: 10.1080/00365521.2020.1858958

263. Sehgal P. et al. Systematic review: safety of mesalazine in ulcerative colitis//Alimentary pharmacology & therapeutics. - 2018. - Т. 47. - N. 12. - С. 1597 - 1609.

264. Sandborn W.J. et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis//Gastroenterology. - 2020. - Т. 158. - N. 8. - С. 2139 - 2149. e14. - 2В

265. Samama M.M., Cohen A.T., Darmon J.Y., Desjardins L., Eldor A., Janbon C., Leizorovicz A., Nguyen H., Olsson C.G., Turpie A.G., Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999 Sep 9; 341(11): 793 - 800. doi: 10.1056/NEJM199909093411103. PMID: 10477777.

266. Gionchetti P. et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis//Alimentary pharmacology & therapeutics. - 1997. - Т. 11. - N. 6. - С. 1053 - 1057.

267. Д.Д. Тарасова, Л.Н. Шилова, М.В. Королева, Современные аспекты терапии язвенного колита N 2 2019 (74) - "Актуальные вопросы фармакотерапии в гастроэнтерологии. Стр. 28 - 32

268. Marshall J.K., Irvine E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997 Jun; 40(6): 775 - 81. doi: 10.1136/gut.40.6.775. PMID: 9245932; PMCID: PMC1027203.

269. Truelove S.C. Treatment of ulcerative colitis with local hydrocortisone. Br Med J. 1956 Dec 1; 2(5004): 1267 - 72. doi: 10.1136/bmj.2.5004.1267. PMID: 13374319; PMCID: PMC2036121.

270. Turunen U.M., , Hakala K., , Sivonen A., Ogren M., Vuoristo M., Valtonen V.V., Miettinen T.A. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998 Nov; 115(5): 1072 - 8. doi: 10.1016/s0016-5085(98) 70076-9. PMID: 9797360.

271. Rutter M.D. et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis//Gastroenterology. - 2006. - Т. 130. - N. 4. - С. 1030 - 1038.

272. Hata K. et al. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population//British journal of cancer. - 2003. - Т. 89. - N. 7. - С. 1232 - 1236.

273. Taylor K., Gibson P.R. Conventional therapy of ulcerative colitis: corticosteroids//Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. - 2017. - С. 399 - 412.

274. Clore J.N., Thurby-Hay L. Glucocorticoid-induced hyperglycemia//Endocrine practice. - 2009. - Т. 15. - N. 5. - С. 469 - 474.

275. Shaye O.A. et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients//Official journal of the American College of Gastroenterology ACG. - 2007. - Т. 102. - N. 11. - С. 2488 - 2494